Overcash, Michael D.
Chillura, Christopher
Fender, Sarah P.
Ewald, Matthew K.
McNair, Aiken McDowell
Nye, Michelle
Blankenship, Clint
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Accepted: 28 January 2021
First Online: 4 March 2021
Declarations
:
: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, provided funding for medical writing support in accordance with Good Publication Practice guidelines (ExternalRef removed) and sponsored the open access fees for this article.
: M.D. Overcash has served as a speaker or advisor for BioPlus, Novartis, Celgene, Bayer HealthCare, Pfizer, Sonoma, IQVIA, Amerita, Ranbaxy, Cipher Pharmaceuticals, Blue Sky, and The Dominion Group. C. Chillura, S.P. Fender, M.K. Ewald, A.M. McNair, M. Nye, and C. Blankenship have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: M. D. Overcash developed the first draft of the article with the help of a medical writer funded by Novartis Pharmaceuticals Corporation. All authors provided input, reviewed the manuscript, and approved submission of this draft for publication.